oncology drug

BOSTON & SOUTH SAN FRANCISCO, Calif., USA, April 1, 2026 Frontier Medicines has announced an exclusive global licensing agreement...

SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...

Tokyo & New York – March 27, 2026 Eisai and Nuvation Bio announced that the European Medicines Agency (EMA)...

Suzhou, China – March 26, 2026 CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong...

TAIPEI, August 28, 2025 — Foresee Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the...